Related Experiment Video
Updated: Nov 19, 2025
miRNA Expression Analyses in Prostate Cancer Clinical Tissues
Published on: September 8, 2015
MiRNA-145-5p expression and prospective molecular mechanisms in the metastasis of prostate cancer
Zhi-Guang Huang1, Yu Sun2, Gang Chen1
1Department of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, P.R. China.
Abstract:
The clinicopathological implication and prospective molecular mechanisms of miRNA-145-5p in the metastasis of prostate cancer (PCa) stand unclear. Herein, it is found that miRNA-145-5p expression was remarkably reduced in 131 cases of metastatic PCa than 1371 cases of localised ones, as the standardised mean differences (SMD) was -1.26 and the area under the curve (AUC) was 0.86, based on miRNA-chip and miRNA-sequencing datasets. The potential targets of miRNA-145-5p in metastatic PCa (n = 414) was achieved from the intersection of miRNA-145-5p transfected metastatic PCa cell line data, differential expression of metastatic PCa upregulated genes and online prediction databases. TOP2A was screened as one of the target hub genes by PPI network analysis, which was adversely related to miRNA-145-5p expression in both metastatic PCa (r = -0.504) and primary PCa (r = -0.281). Gene-chip and RNA-sequencing datasets, as well as IHC performed on clinical PCa samples, showed consistent upregulated expression of TOP2A mRNA and protein in PCa compared with non-PCa. The expression of TOP2A mRNA was also significantly higher in metastatic than localised PCa with the SMD being 1.72 and the AUC of sROC being 0.91. In summary, miRNA-145-5p may participate in PCa metastasis by binding TOP2A and be useful as a biomarker for the detection of metastatic PCa.
Insights
MicroRNA-145-5p is downregulated in metastatic prostate cancer (PCa), suggesting it may inhibit metastasis by targeting TOP2A. This microRNA could serve as a biomarker for detecting metastatic PCa.
Area of Science:
- Oncology
- Molecular Biology
- Biomarker Discovery
Background:
- The role of microRNA-145-5p in prostate cancer (PCa) metastasis is not well understood.
- Identifying molecular mechanisms driving PCa metastasis is crucial for improved diagnostics and therapeutics.
Purpose of the Study:
- To investigate the clinicopathological significance and molecular mechanisms of miRNA-145-5p in prostate cancer metastasis.
- To identify potential molecular targets of miRNA-145-5p involved in PCa progression.
Main Methods:
- Analysis of miRNA expression datasets (miRNA-chip, miRNA-sequencing) from localized and metastatic PCa cohorts.
- Bioinformatic analysis including target prediction, protein-protein interaction (PPI) network analysis.
- Validation of target gene expression using Gene-chip, RNA-sequencing, and immunohistochemistry (IHC) on clinical PCa samples.
Main Results:
- miRNA-145-5p expression was significantly reduced in metastatic PCa compared to localized PCa (SMD = -1.26, AUC = 0.86).
- TOP2A was identified as a key target gene, showing an inverse correlation with miRNA-145-5p expression in both metastatic (r = -0.504) and primary PCa (r = -0.281).
- TOP2A mRNA and protein were consistently upregulated in PCa versus non-PCa tissues, and significantly higher in metastatic than localized PCa (SMD = 1.72, AUC = 0.91).
Conclusions:
- miRNA-145-5p may play a role in inhibiting prostate cancer metastasis by targeting TOP2A.
- The miRNA-145-5p/TOP2A axis presents a potential biomarker for the detection of metastatic prostate cancer.
More Related Videos
Related Concept Videos
01:22MicroRNAs
01:22MicroRNAs
02:30Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...